AnaptysBio (ANAB) Competitors $26.94 -0.05 (-0.19%) Closing price 04:00 PM EasternExtended Trading$26.92 -0.02 (-0.07%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANAB vs. KYMR, CRNX, MOR, ALVO, MIRM, CPRX, GMTX, AMRX, NAMS, and RAREShould you be buying AnaptysBio stock or one of its competitors? The main competitors of AnaptysBio include Kymera Therapeutics (KYMR), Crinetics Pharmaceuticals (CRNX), MorphoSys (MOR), Alvotech (ALVO), Mirum Pharmaceuticals (MIRM), Catalyst Pharmaceuticals (CPRX), Gemini Therapeutics (GMTX), AMNEAL PHARMACEUTICALS (AMRX), NewAmsterdam Pharma (NAMS), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "pharmaceutical products" industry. AnaptysBio vs. Its Competitors Kymera Therapeutics Crinetics Pharmaceuticals MorphoSys Alvotech Mirum Pharmaceuticals Catalyst Pharmaceuticals Gemini Therapeutics AMNEAL PHARMACEUTICALS NewAmsterdam Pharma Ultragenyx Pharmaceutical Kymera Therapeutics (NASDAQ:KYMR) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability. Does the media prefer KYMR or ANAB? In the previous week, AnaptysBio had 3 more articles in the media than Kymera Therapeutics. MarketBeat recorded 6 mentions for AnaptysBio and 3 mentions for Kymera Therapeutics. AnaptysBio's average media sentiment score of 1.10 beat Kymera Therapeutics' score of 1.09 indicating that AnaptysBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Kymera Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AnaptysBio 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, KYMR or ANAB? Kymera Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500. Comparatively, AnaptysBio has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. Do analysts rate KYMR or ANAB? Kymera Therapeutics currently has a consensus price target of $59.11, indicating a potential upside of 29.09%. AnaptysBio has a consensus price target of $47.13, indicating a potential upside of 74.93%. Given AnaptysBio's higher possible upside, analysts plainly believe AnaptysBio is more favorable than Kymera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kymera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 2 Strong Buy rating(s) 3.05AnaptysBio 0 Sell rating(s) 3 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.80 Which has better valuation & earnings, KYMR or ANAB? AnaptysBio has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than AnaptysBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKymera Therapeutics$47.07M63.35-$223.86M-$3.10-14.77AnaptysBio$91.28M8.67-$145.23M-$4.85-5.55 Is KYMR or ANAB more profitable? AnaptysBio has a net margin of -125.70% compared to Kymera Therapeutics' net margin of -409.07%. Kymera Therapeutics' return on equity of -30.11% beat AnaptysBio's return on equity.Company Net Margins Return on Equity Return on Assets Kymera Therapeutics-409.07% -30.11% -25.65% AnaptysBio -125.70%-282.47%-30.79% SummaryKymera Therapeutics beats AnaptysBio on 8 of the 15 factors compared between the two stocks. Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANAB vs. The Competition Export to ExcelMetricAnaptysBioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$792.98M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-5.5521.0428.0720.05Price / Sales8.67284.46448.5799.42Price / CashN/A42.7636.2258.56Price / Book11.568.378.665.87Net Income-$145.23M-$55.19M$3.25B$258.55M7 Day Performance3.94%5.89%4.20%2.23%1 Month Performance15.92%17.63%10.82%12.76%1 Year Performance-27.64%5.09%34.70%19.36% AnaptysBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANABAnaptysBio1.7555 of 5 stars$26.94-0.2%$47.13+74.9%-26.9%$792.98M$91.28M-5.55100News CoveragePositive NewsAnalyst ForecastKYMRKymera Therapeutics3.0325 of 5 stars$45.14-2.3%$59.11+31.0%+6.9%$3.01B$47.07M0.00170Positive NewsCRNXCrinetics Pharmaceuticals3.6692 of 5 stars$30.95-0.5%$69.50+124.6%-43.1%$2.91B$1.04M0.00210Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730ALVOAlvotech2.6708 of 5 stars$8.64+0.1%$16.00+85.2%-21.0%$2.60B$491.98M14.881,032MIRMMirum Pharmaceuticals3.8597 of 5 stars$51.95+0.0%$65.50+26.1%+33.5%$2.57B$336.89M0.00140Positive NewsCPRXCatalyst Pharmaceuticals4.9232 of 5 stars$21.01-0.1%$32.83+56.3%+20.0%$2.57B$491.73M13.3880News CoveragePositive NewsAnalyst RevisionGMTXGemini TherapeuticsN/A$57.770.0%N/A+32.1%$2.50BN/A-57.7730High Trading VolumeAMRXAMNEAL PHARMACEUTICALS3.1391 of 5 stars$7.91-0.8%$11.60+46.6%+8.0%$2.50B$2.79B13.518,100NAMSNewAmsterdam Pharma3.7871 of 5 stars$22.56+1.6%$41.30+83.1%+23.8%$2.49B$45.56M0.004RAREUltragenyx Pharmaceutical4.3623 of 5 stars$26.39+0.3%$83.64+216.9%-39.5%$2.49B$560.23M-4.491,294Upcoming EarningsGap DownHigh Trading Volume Related Companies and Tools Related Companies Kymera Therapeutics Competitors Crinetics Pharmaceuticals Competitors MorphoSys Competitors Alvotech Competitors Mirum Pharmaceuticals Competitors Catalyst Pharmaceuticals Competitors Gemini Therapeutics Competitors AMNEAL PHARMACEUTICALS Competitors NewAmsterdam Pharma Competitors Ultragenyx Pharmaceutical Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANAB) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANAB Stock Alerts